Abstract
Recent evidence suggests that CD38, an ectoenzyme that converts NAD+ to cyclic ADP-ribose (cADPr), may play a role in cytokine-induced airway smooth muscle (ASM) cell hyper-responsiveness, a key feature associated with chronic asthma. In the present study, we investigated the major signaling pathways by which tumor necrosis factor-α (TNFα) induces CD38 expression and its role in regulating gene expression in human ASM cells. Using flow cytometry analyses, TNFα enhanced CD38 expression in a manner that was time-(0–24 h), concentration-(0.1–40 ng/ml), and protein synthesis-(cycloheximide blockade) dependent. A selective agonistic antibody against tumor necrosis factor receptor (TNFR) 1 also augmented CD38 expression, whereas anti-TNFR2 antagonistic antibody did not prevent the TNFα response. Inhibition of the Janus activated kinase/signal transducer and activator of transcription pathways using the soluble inhibitor 2-(1,1-dimethylethyl)-9-fluoro-3,6-dihydro-7H-benz-[h]imidaz[4,5-f]isoquinolin-7-one (DBI) or with neutralizing antibody against interferon β (IFNβ) completely abrogated TNFα-induced CD38 expression at both protein and mRNA levels. Combining TNFα (0.1 and 1 ng/ml) and IFNβ (100 IU/ml) at concentrations alone that had little effect on CD38 expression induced a robust synergistic induction of CD38 mRNA and protein levels. 8-Bromo-cADPr, a cADPr antagonist, significantly augmented TNFα-induced interleukin-6 secretion, whereas regulated on activation normal T cell expressed and secreted secretion was suppressed. 8-Bromo-cADPr, however, did not affect TNFα-induced cell surface expression of intercellular adhesion molecule-1. Our study is the first to demonstrate that IFNβ-dependent activation of CD38 pathway is a novel component by which TNFα differentially regulates the expression of inflammatory genes in ASM cells.
- Received April 1, 2004.
- Accepted May 14, 2004.
- The American Society for Pharmacology and Experimental Therapeutics
MolPharm articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|